IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

December 3, 2021

Study Completion Date

March 31, 2022

Conditions
Gastric Cancer
Interventions
DRUG

IN10018

IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.

DRUG

Docetaxel

Docetaxel 75mg/m2 every 21 days a cycle.

Trial Locations (8)

Unknown

Anyang Tumor Hospital, Anyang

Henan Cancer Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

The Affiliated Hospital of Nanjing University Medical School, Nanjing

The First Hospital of China Medical University, Shenyang

Shanghai East Hospital, Shanghai

The First Affiliated Hospital of XI 'AN Jiaotong University, Xi’an

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors
lead

InxMed (Shanghai) Co., Ltd.

INDUSTRY

NCT05327231 - IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma | Biotech Hunter | Biotech Hunter